Li D.-R.,Chongqing Tumor Institute |
Yang Y.-Q.,National Engineering Center for Biochip at Shanghai |
Tian L.,Chongqing Tumor Institute |
Wang L.,Chongqing Tumor Institute |
And 3 more authors.
Tumor | Year: 2011
Objective: To investigate the correlations of single nucleotide polymorphisms (SNPs) of excision repair cross-complementing gene 1 (ERCC1) Asn118Asn, excision repair cross-complementing gene 2 (ERCC2) Lys751Gln and the X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln with the response to platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods: The gene sequence analysis was used to determine the SNPs of ERCC1 Asn118Asn, ERCC2 Lys751Gln and XRCC1 Arg399Gln in the human peripheral lymphocyte DNAs from 89 patients with NSCLC treated with 2 cycles of platinum-based chemotherapy. The correlations of ERCC1 Asn118Asn, ERCC2 Lys751Gln and XRCC1 Arg399Gln SNPs with the chemosensitivity were analyzed. Results: The overall response rate of platinum-based chemotherapy in 89 NSCLC patients was 29.2%. The genotype distributions of ERCC1 Asn118Asn and ERCC2 Lys751Gln between the response group and the non-response group had no significant difference (P>0.05). The XRCC 1 399Arg/Arg genotype carriers had higher response rate than the Gln genotype (Arg399Gln and Gln399Gln) carriers (76.9% and 23.1%, respectively, P=0.001; odds ratio =5.228, 95% confidence interval =1.776-15.387, P =0.003). Favorable genotypes from polymorphisms in ERCC1, ERCC2 and XRCC1 were involved in the better response to platinum-based chemotherapy in patients with NSCLC. Conclusion: The combination SNPs of ERCC1, ERCC2 and XRCC1 genes may be associated with the high sensitivity to platinum-based chemotherapy in patients with NSCLC. Copyright@2009-2010 Tumor All rights reserved.
Nian W.-Q.,Chongqing tumor Institute |
Chen R.,Chongqing Medical University |
Chen F.-L.,Chongqing Medical University |
Zhang K.-K.,Chongqing Medical University |
Wang D.-L.,Chongqing tumor Institute
Chinese Journal of Cancer Prevention and Treatment | Year: 2012
OBJECTIVE: To screen lung cancer metastasis-associated miRNA by analysis of differentially expressed genes between human lung giant cell carcinoma cell strains of low metastatic 95C and high metastatic 95D using micorna microarray. METHODS: 95C and 95D cells were cultured, the total RNA was isolated and examined The expression profiles of miRNA were detected with miRNA microarray chip. Potential miRNA targets were analyzed by bioinformatics. RESULTS: According to the microarray screening, 36 were up-regulated and 19 down-regulated. Twelve different-expressed miRNA and 1 046 candidate targeted genes were identified that formed a regulatory network. CONCLUSIONS: The miRNA expression profiles of low metastatic 95C and high metastatic 95D are obtained. We present a comprehensive overview of the molecular networks perturbed in the metastasis of lung cancer, discuss several potential key molecular regulatory circuits, and identify microRNA species that may play central roles in facilitating the metastasis of lung cancer.
Xu Y.,Chongqing Medical University |
Wu Y.-Z.,Chongqing Tumor Institute |
Chen C.,Chongqing Tumor Institute |
Chen X.-P.,Chongqing Medical University
Tumor | Year: 2012
Objective: To study whether the expression of heat shock protein 70 (HSP70) in lung tissue induced by GGA (geranylgeranylacetone) has a protective effect on radiation-induced lung injury in mice and its possible mechanism. Methods: One hundred and four health KM mice were randomly divided into control group, GGA group, radiation group and GGA combined with radiation group. Of GGA group and the GGA combined with radiation group before irradiation, the mice were pretreated with GGA at a dose of 600 mg·kg-1·d -1 for 3 d, while the mice of the control and the radiation groups were given 0.9% sodium chloride solution. Then the mice in the radiation group and the GGA combined with radiation group received whole-lung irradiation with X-ray at a single fraction of 20 Gy, while the mice of the other two groups received sham-irradiation. After irradiation, all the mice continued receiving treatment until the appropriate time points for detection. The expressions of HSP70 mRNA and TNF-α (tumor necrosis factor alpha) mRNA in lung tissues were detected by RT-PCR at day 1 and day 3 after irradiation. The positive cells and the distribution of HSP70 proteins were evaluated by immunohistochemistry at day 1 after irradiation. The morphological changes of lung tissues were observed by hematoxylin and eosin staining at day 3 and day 60 after irradiation. The pulmonary fibrosis severity was evaluated by Masson's trichrome staining and hydroxyproline content at day 60. The serum TGF-β1 (transforming growth factor- beta1) level at each time point was measured by ELISA. Results: The typical early stage radiation pneumonitis and the late pulmonary fibrosis were observed in mice in the radiation group. In mice treated by GGA and radiation, HSP70 expression level of the lung tissues was higher than that in the control group or the radiation group. TNF-α mRNA level, serum TGF-β1 level, the severities of radiation pneumonitis and pulmonary fibrosis, and the content of hydroxyproline in the GGA combined with radiation group were lower than those in the radiation group (P < 0.05). There was no significant difference between the GGA group and the control group for all indices. Conclusion: The expression of HSP70 in mice lung tissues induced by regular oral administration of GGA can protect against radiationinduced lung injury, which may be related to the inhibition of expressions of important inflammatory factor TNF-α and fibrosis-related factor TGF-β1. Copyright © 2012 by TUMOR.
Yang T.,Chongqing Tumor Institute |
Shao J.-H.,Chongqing Tumor Institute |
Li Q.-Y.,Chongqing Tumor Institute |
Yu H.-Q.,Chongqing Tumor Institute |
And 4 more authors.
Tumor | Year: 2010
Objective: To evaluate the therapeutic effect of cytokine induced killer (CIK) cells in combination with dendritic cells (DCs) on advanced solid tumor. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from 110 patients with advanced solid tumor. The adherent cells were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF) -alpha, and interleukin-4 (IL-4) to induce DCs. The DCs were sensitized with antigens of autologous tumor cells or extrinsic tumor cell lines to produce Ag-DCs. Suspending cells were cultured with interferon-γ (IFN-γ), interleukin-2 (IL-2), and CD3 monoclonal antibody (CD3 mAb) to prepare CIK cells. Then, the CIK cells were co-cultured with DCs. The phenotype of DCs and CIK cells were analysed using flow cytometry. The autologous CIK cells and DCs were transfused into the patients who had advanced solid tumor. Results: In the 42 patients who were eligible for evaluation, 2 achieved complete remission (CR),9 partial remission (PR) and 15 stable disease (SD). In the 37 patients who were not eligible for evaluation, 25 had efficient response. The immune function was improved and the level of tumor markers were altered significantly compared with those before treatment. Conclusion: CIK cells in combination with DCs treatment is safe and effective in the treatment of advanced malignant solid tumors and has a better application foreground in clinic.